Seth P Lerner

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy
    Kazumasa Matsumoto
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 170:2248-52. 2003
  2. ncbi request reprint Treatment of high-risk, non-muscle-invasive bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Nat Clin Pract Urol 3:398-9. 2006
  3. doi request reprint Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer
    Alvin C Goh
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030 2706, USA
    Urology 72:133-7. 2008
  4. ncbi request reprint The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma
    Seth P Lerner
    Scott Department of Urology, Dan Duncan Cancer Center, Translational and Molecular Medicine Program, Baylor College of Medicine, 6620 Main Suite 1325, Houston, TX 77030, USA
    Curr Treat Options Oncol 10:267-74. 2009
  5. doi request reprint Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Urol Oncol 26:481-5. 2008
  6. doi request reprint Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma
    Seth P Lerner
    Baylor College of Medicine, Scott Department of Urology, Dan Duncan Cancer Center, Department of Pathology, Methodist Hospital, Houston, Texas 77030, USA
    Curr Opin Urol 18:508-12. 2008
  7. pmc Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 27:155-9. 2009
  8. ncbi request reprint Bladder cancer clinical trials
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 23:275-9. 2005
  9. ncbi request reprint The use and abuse of data: nomograms and talking to patients about clinical medicine
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 25:333-7. 2007
  10. ncbi request reprint Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 177:1727-31. 2007

Collaborators

Detail Information

Publications90

  1. ncbi request reprint Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy
    Kazumasa Matsumoto
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 170:2248-52. 2003
    ..We determined whether plasma levels of sE-cadherin are associated with bladder cancer stage and prognosis...
  2. ncbi request reprint Treatment of high-risk, non-muscle-invasive bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Nat Clin Pract Urol 3:398-9. 2006
  3. doi request reprint Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer
    Alvin C Goh
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030 2706, USA
    Urology 72:133-7. 2008
    ..The purpose of this study was to examine the application of OCT in augmenting the diagnosis and staging of bladder lesions...
  4. ncbi request reprint The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma
    Seth P Lerner
    Scott Department of Urology, Dan Duncan Cancer Center, Translational and Molecular Medicine Program, Baylor College of Medicine, 6620 Main Suite 1325, Houston, TX 77030, USA
    Curr Treat Options Oncol 10:267-74. 2009
    ....
  5. doi request reprint Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, and Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Urol Oncol 26:481-5. 2008
    ..Further studies are necessary to establish the role of neoadjuvant and adjuvant therapy for patient with prostatic stroma invasion...
  6. doi request reprint Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma
    Seth P Lerner
    Baylor College of Medicine, Scott Department of Urology, Dan Duncan Cancer Center, Department of Pathology, Methodist Hospital, Houston, Texas 77030, USA
    Curr Opin Urol 18:508-12. 2008
    ..To review the current fund of knowledge about prostatic transitional cell carcinoma and the implications for diagnostic and management strategies particularly as they relate to radical cystectomy...
  7. pmc Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 27:155-9. 2009
    ..Among all patients randomized to maintenance treatment, we also wanted to identify combinations of baseline covariates in order to define prognostic groups for subsequent worsening-free survival...
  8. ncbi request reprint Bladder cancer clinical trials
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 23:275-9. 2005
    ..The present article reviews this important area of clinical trials research...
  9. ncbi request reprint The use and abuse of data: nomograms and talking to patients about clinical medicine
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 25:333-7. 2007
    ..To review the development of nomograms and consortia efforts applying these tools to model outcome predictions associated with radical cystectomy...
  10. ncbi request reprint Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 177:1727-31. 2007
    ..We explored a large prospective data set from the SWOG 8507 randomized trial of maintenance bacillus Calmette-Guerin to better understand this risk and specifically to assess the impact of timing of recurrence on survival...
  11. doi request reprint BCAN Think Tank session 3: Prevention of bladder cancer
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 28:338-42. 2010
    ..These markers, combined with histories of environmental exposure to bladder carcinogens, may provide a tool to identify patients who will benefit from primary prevention...
  12. doi request reprint Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
    BJU Int 108:687-92. 2011
    ..To stratify risk of pathological (p) T2N0 urothelial carcinoma of the bladder after radical cystectomy (RC) based on pathological factors to facilitate the development of adjuvant therapy trials for high-risk patients...
  13. ncbi request reprint Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas 77030, USA
    Urology 61:1053-8. 2003
    ..We tested the hypothesis that preoperative plasma levels of uPA and its specific receptor, uPAR, would predict cancer stage and prognosis in patients with transitional cell carcinoma of the bladder...
  14. ncbi request reprint Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder
    Shanrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Houston, TX 77030, USA
    J Urol 170:985-9. 2003
    ....
  15. doi request reprint Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
    J Urol 185:456-61. 2011
    ..We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival...
  16. ncbi request reprint Case-control analysis of dietary folate and risk of bladder cancer
    Matthew B Schabath
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Nutr Cancer 53:144-51. 2005
    ..These data may have important implications for cancer prevention; however, large, hypothesis-driven, population-based clinical trials will be required to confirm these findings...
  17. pmc Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009
    ....
  18. ncbi request reprint p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
    J Clin Oncol 22:1014-24. 2004
    ..To determine whether p53, p21, pRB, and/or p16 expression is associated with bladder cancer stage, progression, and prognosis...
  19. doi request reprint Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling
    Jonathan M Levitt
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
    Mol Cancer Ther 9:1128-35. 2010
    ..Further clinical development might be warranted in selected human subjects...
  20. doi request reprint Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Clin Cancer Res 14:224-9. 2008
    ..The study aims to evaluate the efficacy and toxicity of fenretinide in preventing tumor recurrence in patients with transitional cell carcinoma (TCC) of the bladder...
  21. ncbi request reprint The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Urol 170:2244-7. 2003
    ..In the current study we tested the hypothesis that urinary uPA and uPAR would add to the predictive ability of urinary nuclear matrix protein 22 (NMP22) and cytology for the diagnosis of bladder cancer...
  22. ncbi request reprint Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance
    Steven S Shen
    Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Hum Pathol 37:726-34. 2006
    ..In summary, presence of prostatic TCC involvement and levels of involvement are significant prognostic factors in patients with bladder cancer...
  23. ncbi request reprint Combining surgery and chemotherapy for invasive bladder cancer: current and future directions
    Gilad E Amiel
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 6:281-91. 2006
    ..Prospective validation of molecular markers and evaluation of novel therapeutic agents, alone or in combination with established cytotoxic agents, provide hope of better outcomes for bladder cancer patients...
  24. ncbi request reprint Neoadjuvant chemotherapy for bladder cancer
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Webster 77598, USA
    Oncology (Williston Park) 21:1673-81; discussion 1686-8, 1691, 1694. 2007
    ..Patients who are either unfit for or refuse radical cystectomy may benefit from neoadjuvant chemotherapy with or without radiation to enable bladder preservation...
  25. ncbi request reprint Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer
    Shahrokh F Shariat
    Baylor Prostate Center, Scott Department of Urology, Baylor College of Medicine, and Methodist Hospital, Houston, Texas 77030 2706, USA
    Urology 61:359-64. 2003
    ..The IGFs are mitogens that have been shown to play a significant role in regulating proliferation and differentiation of bladder cancer cells...
  26. doi request reprint The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder
    Robert S Svatek
    University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 16:4461-7. 2010
    ..Here we address the value of adjuvant chemotherapy in patients undergoing radical cystectomy for UCB in an off-protocol routine clinical setting...
  27. ncbi request reprint Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    Urology 61:1140-5. 2003
    ..To determine whether p53 and p21 expression in bladder carcinoma in situ (CIS) with or without papillary disease can predict disease recurrence, progression, and survival...
  28. doi request reprint Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine
    Weiguo Jian
    Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
    Mol Cancer Ther 8:1772-8. 2009
    ..IHC showed reduced Ki-67 and CD31 and increased cleaved caspase-3 with combination therapy compared with controls. Enzastaurin showed preclinical antitumor activity against human TCC and enhanced the activity of gemcitabine...
  29. ncbi request reprint Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue
    Steven S Shen
    Department of Pathology, The Methodist Hospital and Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer 106:2610-6. 2006
    ..In a previous study the selective ER modulator raloxifene was shown to induce apoptosis in an ERbeta-positive bladder cancer cell line. However, the expression of ERbeta in human bladder cancer has not been thoroughly investigated...
  30. doi request reprint A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma
    Jonathan M Levitt
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 31:234-40. 2013
    ..We hypothesized that the anti-angiogenic and anti-cell-migratory activity of lower concentrations of cisplatin may confer similar anti-tumor activity and demonstrate less nephrotoxicity than conventional cytotoxic concentrations...
  31. doi request reprint Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 30:285-9. 2012
    ..To understand the additional benefits of HAL compared with conventional cystoscopy at the patient level and to explore relationships of urine cytology and CIS...
  32. pmc Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation
    Kristi L Hoffman
    Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA
    Horm Cancer 4:24-35. 2013
    ..These results indicate that antiestrogens may be useful therapeutics in the treatment of bladder cancer by targeting ER and inhibiting growth via multiple mechanisms...
  33. ncbi request reprint High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk
    Meng Chen
    Department of Epidemiology and Urology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Carcinogenesis 28:2160-5. 2007
    ..The contributions of these polymorphisms may jointly affect bladder cancer risk through gene-gene and gene-smoking interactions...
  34. ncbi request reprint Polymorphisms in XPD exons 10 and 23 and bladder cancer risk
    Matthew B Schabath
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Unit 189, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 14:878-84. 2005
    ....
  35. ncbi request reprint Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
    Guru Sonpavde
    Texas Oncology, P A and U S Oncology Research, Houston, TX 77030, USA
    Urol Oncol 27:391-9. 2009
    ..Angiogenesis and VEGF expression correlate with poor outcomes in human urothelial carcinoma. We designed a preclinical study to examine the efficacy of sunitinib alone and in combination with cisplatin against human urothelial carcinoma...
  36. ncbi request reprint Racial/ethnic differences in upper-tract urothelial cancer
    G M Monawar Hosain
    Houston VA Health Services Research and Development Center of Excellence, Houston, Texas, USA
    Ethn Dis 22:295-301. 2012
    ..Our study examined the racial/ethnic differences in patients diagnosed with incident UTUC...
  37. ncbi request reprint Prostatic transitional cell carcinoma: pathologic features and clinical management
    Steven S Shen
    Department of Pathology, The Methodist Hospital and Weill Medical College of Cornell University, 6565 Fannin Street, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:1155-62. 2007
    ..A rational approach for management of pTCC in patients with bladder cancer will be proposed on the basis of our experience and our review of literature...
  38. ncbi request reprint Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort
    Salahaldin A Tahir
    Scott Department of Urology and Department of Pathology, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 12:4872-5. 2006
    ..The value of the combined preoperative markers, prostate-specific antigen (PSA), biopsy Gleason score, and serum cav-1 for predicting biochemical recurrence was also investigated...
  39. doi request reprint Strategies to prevent progression of high-risk bladder cancer at initial diagnosis
    Ja H Ku
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Urol 22:405-14. 2012
    ..As high-risk nonmuscle invasive bladder cancer (NMIBC) has a high propensity to recur and progress, the primary therapeutic goal in patients with high-risk NMIBC is the prevention or delay of disease recurrence and progression...
  40. ncbi request reprint A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer
    Anita L Sabichi
    Department of Medicine, Division of Hematology Oncology, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 4:1580-9. 2011
    ..Our clinical trial results do not show a clinical benefit for celecoxib in preventing NMIBC recurrence but further investigation of COX-2 inhibitors in this setting is warranted...
  41. ncbi request reprint Stage specific lymph node metastasis mapping in radical cystectomy specimens
    Amnon Vazina
    Scott Department of Urology, Baylor College of Medicine, Methodist and Saint Luke s Episcopal Hospitals, Houston, Texas 77030, USA
    J Urol 171:1830-4. 2004
    ..We provide an accurate map of lymph node (LN) metastasis in patients with bladder cancer undergoing radical cystectomy and pelvic lymph node dissection...
  42. ncbi request reprint Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult
    Mohammadbagher Ziari
    Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:4459-60. 2005
  43. ncbi request reprint Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer
    Kazumasa Matsumoto
    Scott Department of Urology, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
    Urology 66:441-6. 2005
    ..Low levels of CAR are associated with decreased efficiency of adenovirus-mediated gene transduction of bladder transitional cell carcinoma...
  44. ncbi request reprint Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    J Urol 171:626-30. 2004
    ....
  45. ncbi request reprint Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  46. doi request reprint Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer
    Vitaly Margulis
    Department of Urologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 101:114-9. 2009
    ....
  47. ncbi request reprint Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder
    Shahrokh F Shariat
    Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    J Urol 169:938-42. 2003
    ..We describe cyclooxygenase-2 (COX-2) expression patterns in patients with carcinoma in situ and/or stage T1 transitional cell carcinoma. We determined whether expression is associated with clinical outcome in these patients...
  48. ncbi request reprint Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancer
    Arup Chakraborty
    Department of Pediatrics, Section of Leukocyte Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Urology 63:177-83. 2004
    ..In neutrophils, G-CSF acts through its receptor to enhance adhesion and migration. A significant fraction of bladder carcinoma has been reported to express both G-CSF and G-CSFR...
  49. ncbi request reprint Centrosomal abnormality is common in and a potential biomarker for bladder cancer
    Feng Jiang
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 106:661-5. 2003
    ..Centrosomal abnormalities appear to be intrinsic to aneuploidy and tumorigenesis and may be potential markers for early detection of bladder cancer...
  50. ncbi request reprint Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma
    Roberto Casella
    the Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Cancer 95:2494-9. 2002
    ....
  51. ncbi request reprint Dietary carotenoids and genetic instability modify bladder cancer risk
    Matthew B Schabath
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Nutr 134:3362-9. 2004
    ..18; 95% CI, 1.13-4.22). This study provides evidence of a preventive role for carotenoids in bladder cancer, and these data may have important implications for cancer prevention, especially for individuals susceptible to DNA damage...
  52. doi request reprint Bladder cancer detection, treatment and outcomes: opportunities and challenges
    David M Latini
    Scott Department of Urology and Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Urology 75:334-9. 2010
    ..Increasing national attention to BlCa is likely to improve disease burden and patient quality of life...
  53. ncbi request reprint Bladder cancer screening program for a petrochemical cohort with potential exposure to beta-napthylamine
    Sarah A Felknor
    University of Texas Health Science Center at Houston, School of Public Health, Southwest Center for Occupational and Environmental Health, Houston, TX, USA
    J Occup Environ Med 45:289-94. 2003
    ..Original personnel records are often incomplete, making cohort identification important. Personal contact and follow-up are key elements of successful recruitment and retention...
  54. ncbi request reprint The angiopoietin-tie2 pathway is a potential therapeutic target in urothelial carcinoma
    Weiguo Jian
    Department of Urology, Baylor College of Medicine, Houston, TX, U S A
    Anticancer Res 34:3377-82. 2014
    ..008) by CEP-11981. Conclusion: CEP-11981 demonstrated a significant pre-clinical activity against human UC xenografts, which was attributable primarily to effects on TIE2 receptor. ..
  55. ncbi request reprint The preclinical activity of lenalidomide in indolent urothelial carcinoma
    Weiguo Jian
    Department of Urology, Baylor College of Medicine, Houston, TX, U S A
    Anticancer Res 34:3383-9. 2014
    ..Clinical trials are warranted in patients with indolent UC. ..
  56. pmc Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen
    Suraj Konnath George
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX
    Transl Oncol 6:244-55. 2013
    ..Administration of tamoxifen should be tested as a chemopreventive strategy for patients at high risk for bladder cancer recurrence...
  57. doi request reprint Innovations in radical cystectomy and pelvic lymph node dissection
    Lambros Stamatakis
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Semin Oncol 39:573-82. 2012
    ..Anatomic pelvic and iliac lymphadenectomy is crucial for precise pathologic staging and may improve patient survival by removing micrometastatic disease...
  58. ncbi request reprint Alternatives to cytology in the management of non-muscle invasive bladder cancer
    Gilad E Amiel
    Baylor College of Medicine, 6560 Fannin Street, Suite 2100, Houston, TX 77030, USA
    Curr Treat Options Oncol 5:377-89. 2004
    ....
  59. ncbi request reprint Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro
    C T F Freund
    Scott Department of Urology, Baylor College of Medicine, and The Methodist Hospital, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
    Urol Oncol 21:197-205. 2003
    ..Additional studies exploring the role of methotrexate in enhancing the tk-GCV system are required. Investigation of other, potentially more synergistic chemotherapeutic agents in combination with tk-GCV is warranted...
  60. ncbi request reprint Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer
    Ben Andrews
    Scott Department of Urology, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    J Urol 167:1475-81. 2002
    ..We tested the hypothesis that preoperative plasma IL-6 and IL-6sR levels would predict cancer stage and prognosis in patients with transitional cell carcinoma of the bladder...
  61. ncbi request reprint Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study
    Anita L Sabichi
    University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 12:2178-84. 2006
    ..Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue...
  62. ncbi request reprint Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk
    Hua Zhao
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Urol 169:714-7. 2003
    ..Because insulin-like growth factors (IGFs) and their binding proteins have been implicated in the development of prostate, breast, colon and lung cancer, we examined the role of IGF-1 and IGF binding protein-3 levels in bladder cancer risk...
  63. doi request reprint Application of new technology in bladder cancer diagnosis and treatment
    Alvin C Goh
    Scott Department of Urology, Baylor College of Medicine, 6620 Main Street, Suite 1325, Houston, TX 77030, USA
    World J Urol 27:301-7. 2009
    ..We aim to provide an overview of the strengths and weaknesses of these imaging modalities and examine their potential impact on the diagnosis and management of bladder cancer...
  64. ncbi request reprint Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder
    Mohammadbagher Ziari
    Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:4458-9. 2005
  65. doi request reprint Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review
    Ja Hyeon Ku
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    BJU Int 110:630-6. 2012
    ..The clinical utility of urine survivin as a bladder tumour marker identified in the present study remains to be elucidated...
  66. ncbi request reprint Advances in diagnosis and therapy of transitional cell carcinoma of the bladder
    Seth P Lerner
    Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
    Urol Oncol 24:324-5. 2006
  67. ncbi request reprint Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy
    Yair Lotan
    Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9110, USA
    J Clin Oncol 23:6533-9. 2005
    ..We hypothesized that bladder cancer patients with associated lymphovascular invasion (LVI) are at increased risk of occult metastases...
  68. ncbi request reprint Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Urol 176:2414-22; discussion 2422. 2006
    ..We present the characteristics and outcomes of a large, contemporary, consecutive series of patients treated with radical cystectomy and pelvic lymphadenectomy for transitional cell carcinoma of the bladder...
  69. ncbi request reprint Perioperative chemotherapy in locally advanced bladder cancer
    Walter M Stadler
    Department of Medicine, Section of Hematology Oncology and Urology, University of Chicago, Chicago, IL 60637, USA
    Lancet 361:1922-3. 2003
  70. ncbi request reprint Precystectomy nomogram for prediction of advanced bladder cancer stage
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    Eur Urol 50:1254-60; discussion 1261-2. 2006
    ..To evaluate precystectomy prediction of pT and pN stages at cystectomy...
  71. ncbi request reprint Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    J Urol 176:1354-61; discussion 1361-2. 2006
    ....
  72. ncbi request reprint Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    Eur Urol 51:152-60. 2007
    ..The aim of this study was to assess whether presence of concomitant CIS has a detrimental effect on cancer control after radical cystectomy...
  73. ncbi request reprint Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Eur Urol 51:137-49; discussion 149-51. 2007
    ..We compared clinical and pathologic staging in a large, contemporary, consecutive series of patients who were treated with radical cystectomy and pelvic lymphadenectomy, and determined the effect of stage discrepancy on outcomes...
  74. ncbi request reprint Nomograms provide improved accuracy for predicting survival after radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, and The Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    Clin Cancer Res 12:6663-76. 2006
    ....
  75. ncbi request reprint Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder
    Craig G Rogers
    Bladder Cancer Research Consortium, James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287 2101, USA
    J Urol 175:2048-53; discussion 2053. 2006
    ..We conducted a multi-institutional retrospective study of patients with bladder cancer treated with radical cystectomy to assess the impact of nonTCC histology on bladder cancer specific outcomes...
  76. ncbi request reprint Cancer specific outcomes in patients with pT0 disease following radical cystectomy
    Ganesh S Palapattu
    James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    J Urol 175:1645-9; discussion 1649. 2006
    ..We assessed clinical outcomes in patients found to have no evidence of disease, ie pT0, in the cystectomy specimen following radical cystectomy for transitional cell carcinoma...
  77. ncbi request reprint A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome
    Matthew E Nielsen
    The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    BJU Int 100:1015-20. 2007
    ....
  78. ncbi request reprint Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival
    Patrick J Bastian
    The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA
    BJU Int 101:450-4. 2008
    ....
  79. ncbi request reprint Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Cancer 112:315-25. 2008
    ....
  80. ncbi request reprint Neoadjuvant chemotherapy preceding cystectomy for bladder cancer
    Guru Sonpavde
    Texas Oncology, P A and US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Opin Pharmacother 9:1885-93. 2008
    ..Occult micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced, muscle-invasive transitional cell carcinoma of the bladder...
  81. ncbi request reprint Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical School 5323 Harry Hines Blvd, Dallas, Texas 75390 9110, USA
    Eur Urol 48:69-76. 2005
    ..To test the hypothesis that elevated urinary levels of soluble E-cadherin (sE-cadherin) would aid in the detection of transitional cell carcinoma (TCC) of the urinary bladder...
  82. doi request reprint Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study
    Jochen Walz
    Cancer Prgonosis and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    BJU Int 101:1356-61. 2008
    ....
  83. doi request reprint Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy
    Amit Gupta
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 71:302-7. 2008
    ..The aim of the present study was to assess the pathologic features and clinical outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma (UCBC) treated with radical cystectomy...
  84. ncbi request reprint Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy
    Matthew E Nielsen
    The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    Eur Urol 51:699-706; discussion 706-8. 2007
    ..The aim of our study was to assess the impact of patient age on pathological characteristics and recurrence-free and disease-specific survival following RC...
  85. ncbi request reprint Molecular markers in bladder cancer
    Shahrokh F Shariat
    Department of Urology, UT Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Curr Opin Urol 18:1-8. 2008
    ..Bladder cancer is a diverse disease whose molecular phenotypes are being elucidated. In this review, we summarize currently known molecular pathways and associated markers in bladder cancer...
  86. ncbi request reprint Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma
    Guru Sonpavde
    U S Oncology Research, Webster, Texas, USA
    Urology 69:1221-6. 2007
    ..To evaluate estrogen receptors as a therapeutic target for human bladder cancer...
  87. ncbi request reprint Chemoprevention of bladder cancer
    Dragan J Golijanin
    Urology Department, University of Rochester Medical Center, 601 Elmwood Avenue, P O Box 656, Rochester, NY 14642, USA
    World J Urol 24:445-72. 2006
  88. ncbi request reprint Editorial comment on: Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light
    Seth P Lerner
    Eur Urol 52:1708-9. 2007
  89. ncbi request reprint Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 68:538-42. 2006
    ..To describe the cancer-specific outcomes of patients with pathologic carcinoma in situ (CIS) only at radical cystectomy...
  90. ncbi request reprint Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1
    Isaac Yi Kim
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Res 64:7355-60. 2004
    ....